The development of therapies targeting specific molecular pathways is for both oncologic and non- oncologic diseases subject of extensive research. With an expanding number of these available therapies, molecular imaging may support in selecting patients that can benefit from these therapies. One potential molecular imaging target is αvβ3 integrin, expressed on activated endothelial cells required in the formation of new blood vessels. Integrin αvβ3 expression is a hallmark of angiogenesis and is induced in response to microenvironmental or genetic changes.